anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study participants will attend a one-day testing session at the Movement Laboratory, University of Liverpool. Participants will be subjected to several standing and walking tests while wearing three types of footwear in a randomised order: (i) a minimal shoe, (ii) a conventional shoe, and (iii) barefoot. Participants' physical function, stability during standing and walking and an activity of lower leg muscles will be assessed in each of those three footwear conditions. Participants will also be asked about perceptions of footwear, regarding a minimal shoe and a conventional shoe. At the end of assessments, participants will be asked to complete several walking bouts while wearing a minimal shoe with "smart" shoe insoles, to determine "smart" insoles' validity in obtaining gait characteristics against a gold standard measure. Finally, those participants who volunteer to take part in a two-week follow-up study, will be asked to wear the minimal shoes with "smart" insoles during daily life for two weeks, After two weeks, they will be asked to fill in an online questionnaire asking them about total time they used the minimal shoes and insoles and about how satisfied they were with them.
The invention mainly discloses vitamin powder and a preparation method of the vitamin powder. The vitamin comprises the following components in mass percentage: 5-60% of fat soluble vitamin, 30-70% of wall material, 5-30% of assistant wall material, 0.5-2% of emulsifier, 0.1-2% of antioxidant and 0.1-3% of cross linking agent. The invention further relates to a preparation method of the vitamin powder. By using a microencapsulation technique, the fat soluble vitamin oil (e.g. vitamin A, vitamin D3, vitamin E and vitamin K) is embedded to a micro-capsule, the wall material used in the embeeding process is starch sodium octenylsuccinate, the vitamin oil is embeeded in the wall and then the micro-capsule is subjected to cross linkage, mist spraying and drying are carried out to form the vitamin powder, and the embedding rate of the vitamin is more than 95.3%. According to the invention, the process is simple, the cost is low, the obtained vitamin powder is not soluble in water, high in oil loading amount and good in flowability, and can be used in the fields such as foods, daily-used industrial chemicals and medicines.
We aimed to investigate the immediate effect of best practice education (with and without pain science messages) and structure-focused education on reassurance among people with rotator cuff-related shoulder pain. We conducted a 3-arm, parallel-group, randomised experiment. People with rotator cuff-related shoulder pain were randomised (1:1:1) to (1) best practice education (highlights that most shoulder pain is not serious or a good indicator of tissue damage and recommends simple self-management strategies); (2) best practice education plus pain science messages (which attempt to improve understanding of pain); and (3) structure-focused education (highlighting that structural changes are responsible for pain and should be targeted with treatment). Coprimary outcomes were self-reported reassurance that no serious condition is causing their pain and continuing with daily activities is safe. Secondary outcomes measured management intentions, credibility and relevance of the education, and similarity to previous education. Two thousand two hundred thirty-seven participants were randomised and provided primary outcome data. Best practice education increased reassurance that no serious condition is causing their pain (estimated mean effect 0.5 on a 0-10 scale, 95% confidence interval [CI] 0.2-0.7) and continuing with daily activities is safe (0.6, 95% CI 0.3-0.8) compared with structure-focused education . Adding pain science messages to best practice education slightly increased both measures of reassurance (0.2, 95% CI 0.0-0.4). Clinicians treating patients with rotator cuff-related shoulder pain should highlight that most shoulder pain is not serious or a good indicator of tissue damage and recommend simple self-management strategies. The benefit of adding pain science messages is small.
Chronic hand and wrist pain is a common presenting complaint. The intricate anatomy results in a variety of pain generators-multiple bones, articular cartilage, intrinsic ligaments, triangular fibrocartilage complex, joint capsules and synovium, tendons and tendon sheaths, muscles, and nerves-in a compact space. The need for imaging and the choice of the appropriate imaging modality are best determined by the patient's presentation, physical examination, and the clinician's working differential diagnosis. Radiography is usually appropriate as the initial imaging study in the evaluation of chronic hand or wrist pain. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
Monolithic dosage form comprises: at least one first active ingredient and second active ingredient, where the first active ingredient at a pH value of 7 and a temperature of 22[deg] C has a solubility of less than 0.01 mg/ml, and the second active ingredient at a pH value of 7 and a temperature of 22[deg] C has a solubility that exceeds the solubility of the first active ingredient at pH 7 and 22[deg] C by at least one order of magnitude; at least one emulsifier having a polyalkylene oxide structural motif (I); and at least one retarding agent. Monolithic dosage form comprises: at least one first active ingredient and second active ingredient, where the first active ingredient at a pH value of 7 and a temperature of 22[deg] C has a solubility of less than 0.01 mg/ml, and the second active ingredient at a pH value of 7 and a temperature of 22[deg] C has a solubility that exceeds the solubility of the first active ingredient at a pH value 7 and 22[deg] C by at least one order of magnitude; at least one emulsifier having a polyalkylene oxide structural motif of formula (R1-O-[CH 2-CH 2-O-] n-R2) (I); and at least one retarding agent, where the sum of the amount of retarding agent and the emulsifier is at least 40 wt.% and the mass ratio of the second active ingredient to the retarding agent is less than 1:1. R1, R2 : H, alkyl, glyceride or polyalkylene oxide; and n : 4. An independent claim is included for producing the dosage form, comprising (a) mixing components of the dosage form, (b) granulating the components, and (c) making the monolithic dosage form from the granules. ACTIVITY : Analgesic; Neuroleptic; Cardiovascular-Gen.; Antimigraine; CNS-Gen.; Respiratory-Gen.; Gastrointestinal-Gen.; Fungicide; Vasotropic; Antiallergic; Auditory. MECHANISM OF ACTION : None given.
Many surgeons consider the postoperative treatment after sinus surgery as important for the outcome as the surgery itself. However, postoperative treatment regimes differ considerably between surgeons. They include non-intervention, frequent in-office endoscopic debridement, stenting of the middle meatus, saline douching or irrigation of the nose, or combinations of these measures in various ways. The lack of consensus is unfortunate. It indicates a lack of knowledge about how to treat these patients optimally after surgery. This is partly due to a lack of internationally acknowledged randomised, comparative, prospective studies on the effects of the various postoperative measures and their interactions. Accordingly, some patients may receive a too intensive postoperative follow up, with unnecessary frequent visits with the doctor, unnecessary bleeding and inconvenience from unnecessary debridement/cleaning of the nose, and increased costs due to unnecessary medication. Conversely, there may be patients that receive too little attention in the postoperative period, and thus may have a suboptimal result of the operation.

Frequent cleaning/debridement of the nose after sinus surgery is believed to improve the outcome of functional endoscopic sinus surgery (FESS). However, the scientific data on its effects are limited. The purpose of this study was to evaluate the effects of cleaning/ debridement of the middle meatus 5-7 days and 12-14 days after sinus surgery in a randomized, partly blinded, controlled clinical trial.
PURPOSE:To obtain a liposome, composed of a long-chain active amide and a lipid capable of forming the liposome, useful as drug carriers, immulological analytical reagents, etc., and capable of modifying surfaces. CONSTITUTION:The objective substance is obtained by mixing <= 50 wt.% compound expressed by the formula [R1 is hydrophobic group; R2 and R3 are organic group (including H) or R2 and R3 may be linked to form a ring or double bond; X and Y are O or S] with a liposome constituent material and preparing a liposome according to a well-known method. The existing lipids except phosphatidylethanolamine and phosphatidylserine which are used as the constituent material of the liposome are cited as the constituent material of the liposome. Examples thereof are egg yolk lecithin and dipalmitoylphosphatidylcholine. Surface-modified liposomes immobilizing various substrates can be readily obtained by mixing the aforementioned lioposome with the substrates (e.g. amino acid-containing peptides or antigen- or antibody- containing proteins) having amino groups and/or thiol groups.
Hydroxytyrosol (HT) or dimethyl fumarate (DMF), activators of nuclear factor erythroid 2-related factor 2 (Nrf2), may reduce obesity in high-fat diet (HFD)-fed animals; nevertheless, the role of these activators on skin tissue repair of HFD-fed animals was not reported. This study investigated whether HT or DMF could improve skin wound healing of HFD-fed obese animals. Mice were fed with an HFD, treated with HT or DMF, and full-thickness skin wounds were created. Macrophages isolated from control and obese animals were treated in vitro with HT. DMF, but not HT, reduced the body weight of HFD-fed mice. Collagen deposition and wound closure were improved by HT or DMF in HFD-fed animals. HT or DMF increased anti-inflammatory macrophage phenotype and protein Nrf2 levels in wounds of HFD-fed mice. Lipid peroxidation and protein tumor necrosis factor-α levels were reduced by HT or DMF in wounds of HFD-fed animals. In in vitro, HT stimulated Nrf2 activation in mouse macrophages isolated from obese animals. In conclusion, HT or DMF improves skin wound healing of HFD-fed mice by reducing oxidative damage and inflammatory response. HT or DMF may be used as a therapeutic strategy to improve the skin healing process in individuals with obesity.
Under sterile precautions, a high frequency linear array transducer \[6-13 Megahertz (MHz), Sonosite M-Turbo\] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is adjacent to the C5 and C6 roots. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
OBJECTIVE: When the peritoneal cavity cannot serve as the distal shunt terminus, nonperitoneal shunts, typically terminating in the atrium or pleural space, are used. The comparative effectiveness of these two terminus options has not been evaluated. The authors directly compared shunt survival and complication rates for ventriculoatrial (VA) and ventriculopleural (VPl) shunts in a pediatric cohort.
METHODS: The Hydrocephalus Clinical Research Network Core Data Project was used to identify children ≤ 18 years of age who underwent either VA or VPl shunt insertion. The primary outcome was time to shunt failure. Secondary outcomes included distal site complications and frequency of shunt failure at 6, 12, and 24 months.
RESULTS: The search criteria yielded 416 children from 14 centers with either a VA (n = 318) or VPl (n = 98) shunt, including those converted from ventriculoperitoneal shunts. Children with VA shunts had a lower median age at insertion (6.1 years vs 12.4 years, p < 0.001). Among those children with VA shunts, a hydrocephalus etiology of intraventricular hemorrhage (IVH) secondary to prematurity comprised a higher proportion (47.0% vs 31.2%) and myelomeningocele comprised a lower proportion (17.8% vs 27.3%) (p = 0.024) compared with those with VPl shunts. At 24 months, there was a higher cumulative number of revisions for VA shunts (48.6% vs 38.9%, p = 0.038). When stratified by patient age at shunt insertion, VA shunts in children < 6 years had the lowest shunt survival rate (p < 0.001, log-rank test). After controlling for age and etiology, multivariable analysis did not find that shunt type (VA vs VPl) was predictive of time to shunt failure. No differences were found in the cumulative frequency of complications (VA 6.0% vs VPl 9.2%, p = 0.257), but there was a higher rate of pneumothorax in the VPl cohort (3.1% vs 0%, p = 0.013).
CONCLUSIONS: Shunt survival was similar between VA and VPl shunts, although VA shunts are used more often, particularly in younger patients. Children < 6 years with VA shunts appeared to have the shortest shunt survival, which may be a result of the VA group having more cases of IVH secondary to prematurity; however, when age and etiology were included in a multivariable model, shunt location (atrium vs pleural space) was not associated with time to failure. The baseline differences between children treated with a VA versus a VPl shunt likely explain current practice patterns.
Process for deodorisation of Pongamia oil (i.e. the oil extracted by pressing or solvent extraction from the seeds of Pongamia glabra as a brown or orange opaque liquid with a strong disagreeable odour) comprises subjecting the oil to steam treatment under an applied vacuum for a time sufficient to achieve the desired deodorisation. Preferably the steam input is equivalent to 0.5-3 wt. % of the oil to be deodourised per hour of the treatment. The treatment conditions are e.g a temperature of 150-200 deg C, a vacuum of 2-5 mm Hg and a treatment time of 1-10 h. Preferably the oil is held under a flux of nitrogen during the heating up and cooling down periods. The deodourised oil preferably has a peroxide index of about 0.5-1.5 meq O2/kg and an oleic acidity of about 1-5 % (w/w). The oil preferably has a fatty acid cut of approximately (by wt.) 10 % palmitic acid, 7 % stearic acid, 52 % oleic acid, 20 % linoleic acid, 5 % linolenic acid, 1.5 % arachidic acid and 4.5 % behenic acid. The oil preferably contains a non-saponifiable fraction of about 2.5 %.
Patients will continue to work with the LOOP MDT. However, exercise and physical activity advise will be taken over by an exercise specialist. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
Mycophenolate mofetil (MMF) has demonstrated teratogenic effects in humans [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. Mycophenolate Mofetil Capsules, USP should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in Mycophenolate Mofetil Capsules, USP. Follow applicable special handling and disposal procedures1.

Mycophenolate Mofetil Capsules, USP are available as follows:

250 mg – hard gelatin capsules with a light blue opaque cap and a bright orange opaque body, filled with a white to off-white powder with small agglomerates; imprinted with "TEVA" on the cap and "7334" on the body. They are available in bottles of 100 and 500 capsules. (NDC 0093-7334-01 and NDC 0093-7334-05)
A similar to BE-based recruitment video using a standard biological approach on teenagers' decision to enroll in a clinical study will be used as comparison. Phase 2 will focus on patients that would be enrolled into the control arm of a clinical trial with a control intervention, Manage My Pain application.
BACKGROUND: Chronic kidney disease (CKD) is highly prevalent, affecting approximately 11% of US adults. Multiple studies have evaluated a potential association between CKD and urinary tract malignancies. Summary estimates of urinary tract malignancy risk in CKD patients with and without common co-existing conditions may guide clinical practice recommendations.
METHODS: Four electronic databases were searched for original cohort studies evaluating the association between CKD and urinary tract cancers (kidney cancer and urothelial carcinoma) through 25 May 2023, in persons with at least moderate CKD and no dialysis or kidney transplantation. Quality assessment was performed for studies meeting inclusion criteria using the Newcastle-Ottawa Scale. Meta-analysis with a random-effects model was performed for unadjusted incidence rate ratios (IRR) as well as adjusted hazard ratios (aHR) for confounding conditions (diabetes, hypertension and/or tobacco use), shown to have association with kidney cancer and urothelial carcinoma. Sub-analysis was conducted for estimates associated with CKD stages separately.
RESULTS: Six cohort studies with 8 617 563 persons were included. Overall, the methodological quality of the studies was good. CKD was associated with both higher unadjusted incidence and adjusted hazard of kidney cancer (IRR 3.36, 95% confidence interval (CI) 2.32-4.88; aHR 2.04, 95% CI 1.77-2.36) and urothelial cancer (IRR 3.96, 95% CI 2.44-6.40; aHR 1.35, 95% CI 1.22-1.50) compared with persons without CKD. Examining incident urinary tract cancers by CKD severity, risks were elevated in stage 3 CKD (kidney aHR 1.89, 95% CI 1.56-2.30; urothelial carcinoma aHR 1.35, 95% CI 1.20-1.52) as well as in stages 4/5 CKD (kidney cancer aHR 2.30, 95% CI 2.00-2.66; urothelial carcinoma aHR 1.24, 95% CI 1.04-1.49).
CONCLUSIONS: Even moderate CKD is associated with elevated risk of kidney cancer and urothelial carcinoma. Providers should consider these elevated risks when managing individuals with CKD, particularly when considering evaluation for the presence and etiology of hematuria.
CBT followed Craske \& Barlow´s (2007) manual, which contains a session-by-session description treatment of panic disorder with CBT. The treatment included the following components: (a) psychoeducation about the nature of anxiety and panic, (b) diaphragmatic breathing training, (c) identification and correction of maladaptive thoughts about anxiety and its consequences, (d) exposure to interoceptive sensations, and (e) exposure to feared situations.
The invention discloses an isolated antibody and uses thereof. The isolated antibody comprises a heavy chain variable region and a light chain variable region, and the isolated antibody comprises one or more of the following technical characteristics: the heavy chain variable region comprises the amino acid sequence CDR-H1 as shown in SEQ ID No. 1; the heavy chain variable region comprises CDR-H2 with an amino acid sequence shown as SEQ ID No. 2; the heavy chain variable region comprises CDR-H3 with an amino acid sequence shown as SEQ ID No. 3; the light chain variable region comprises the amino acid sequence CDR-L1 as shown in SEQ ID No. 4; the light chain variable region comprises CDR-L2 of the amino acid sequence VAS; the light chain variable region comprises CDR-L3 of the amino acid sequence shown in SEQ ID No. 5. The isolated antibody can efficiently target the CD4 antigen, efficiently enrich the CD4T cells, and the CAR-T cells prepared by the enriched CD4T cells can be activated by the antigen specificity.
Society has always understood individuals with intellectual disabilities from a stance of deficiency, resulting in limited expectations and prospects for school-going adolescents with intellectual disabilities. The study used the social model of disability to explore teachers' perceptions of enablers to enhance school-based adolescents with intellectual disabilities' learning and took cognisance of a wave of policies aimed at including adolescents with intellectual disabilities in mainstream education. A qualitative narrative approach was used for the study. Using a narrative methodological framework, unstructured interview questions were posed to elicit teachers' perceptions of enablers to enhance adolescents with intellectual disabilities' learning. A non-probability purposive sampling method was used to select teachers working with school-based learners with intellectual disabilities. Five themes emerged from the analysis: therapeutic setting; learners' resilience; parental support; teaching strategies; and community involvement as enablers for enhancing learning for adolescents with intellectual disabilities. Policy implications are also provided in the study.
BACKGROUND: Schizophrenia research reveals sex differences in incidence, symptoms, genetic risk factors, and brain function. However, a knowledge gap remains regarding sex-specific schizophrenia alterations in brain function. Schizophrenia is considered a dysconnectivity syndrome, but the dynamic integration and segregation of brain networks are poorly understood. Recent advances in resting-state functional magnetic resonance imaging allow us to study spatial dynamics, the phenomenon of brain networks spatially evolving over time. Nevertheless, estimating time-resolved networks remains challenging due to low signal-to-noise ratio, limited short-time information, and uncertain network identification.
METHODS: We adapted a reference-informed network estimation technique to capture time-resolved networks and their dynamic spatial integration and segregation for 193 individuals with schizophrenia and 315 control participants. We focused on time-resolved spatial functional network connectivity, an estimate of network spatial coupling, to study sex-specific alterations in schizophrenia and their links to genomic data.
RESULTS: Our findings are consistent with the dysconnectivity and neurodevelopment hypotheses and with the cerebello-thalamo-cortical, triple-network, and frontoparietal dysconnectivity models, helping to unify them. The potential unification offers a new understanding of the underlying mechanisms. Notably, the posterior default mode/salience spatial functional network connectivity exhibits sex-specific schizophrenia alteration during the state with the highest global network integration and is correlated with genetic risk for schizophrenia. This dysfunction is reflected in regions with weak functional connectivity to corresponding networks.
CONCLUSIONS: Our method can effectively capture spatially dynamic networks, detect nuanced schizophrenia effects including sex-specific ones, and reveal the intricate relationship of dynamic information to genomic data. The results also underscore the clinical potential of dynamic spatial dependence and weak connectivity.